Top stories

View all news

The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.

The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…

Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…

COVAX vaccine roll-out

>54 million COVAX vaccines shipped
OWP
121 participants

As of 7 May 2021

COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.

Learn more

The COVID-19 vaccine race

Pre-clinical
184vaccines
are being explored in lab experiments and animals
PHASE 1
32 vaccines
are undergoing safety tests in healthy young individuals
Phase 2
35vaccines
are being tested in broader groups of people
Phase 3
25vaccines
are in large international trials to test their impact on COVID-19
IN USE
14vaccines
are currently being offered to the general population
Phase 4
4vaccines
are being monitored in the wider population after being approved

Source: WHO

Learn more

COVID-19 vaccines

Accurate, evidence-based information about COVID-19 vaccines to provide people with essential facts about the vaccines that will help end this crisis.

Learn more

Accurate, evidence-based information about COVID-19 vaccines to provide people with essential facts about the vaccines that will help end this crisis.

Learn more

#VaccinesWork

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Top VaccinesWork stories

View all stories

Meningitis affects more than 30,000 people in Africa every year. Scientists use weather data to predict location and scale of impending cases. The prediction helps country-level health services to plan emergency responses.

Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.

We cannot look back in the future and know we could have done more.

Supported countries

Supported Countries

Our impact

Syringe >822 million children immunised
First aid locator >14 million future deaths prevented
Transitioned 16 countries transitioned from Gavi support
Billions >150 US$ billion in economic benefits for countries (2000–2017)
Children 85% of the world's children reached by routine immunisation

Our mission: protect people's health

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Our partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Like. Follow. Share.

    Subscribe to our newsletter